1127 related articles for article (PubMed ID: 32006461)
1. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006282. PubMed ID: 22513940
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment for spinal muscular atrophy types II and III.
Bosboom W; Vrancken AF; van den Berg LH; Wokke JH; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006282. PubMed ID: 19160275
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006281. PubMed ID: 22161399
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy type I.
Bosboom W; Vrancken AF; van den Berg LH; Wokke J; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006281. PubMed ID: 19160274
[TBL] [Abstract][Full Text] [Related]
9. Physical exercise training for type 3 spinal muscular atrophy.
Bartels B; Montes J; van der Pol WL; de Groot JF
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012120. PubMed ID: 30821348
[TBL] [Abstract][Full Text] [Related]
10. Respiratory muscle training in children and adults with neuromuscular disease.
Silva IS; Pedrosa R; Azevedo IG; Forbes AM; Fregonezi GA; Dourado Junior ME; Lima SR; Ferreira GM
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011711. PubMed ID: 31487757
[TBL] [Abstract][Full Text] [Related]
11. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Bourke JP; Bueser T; Quinlivan R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
[TBL] [Abstract][Full Text] [Related]
13. Interventions for eye movement disorders due to acquired brain injury.
Rowe FJ; Hanna K; Evans JR; Noonan CP; Garcia-Finana M; Dodridge CS; Howard C; Jarvis KA; MacDiarmid SL; Maan T; North L; Rodgers H
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011290. PubMed ID: 29505103
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.
Rolim LC; da Silva EM; Flumignan RL; Abreu MM; Dib SA
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD011265. PubMed ID: 31201734
[TBL] [Abstract][Full Text] [Related]
15. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E; Ellis C; Brassington R; Sathasivam S; Young CA
Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746
[TBL] [Abstract][Full Text] [Related]
16. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
[TBL] [Abstract][Full Text] [Related]
17. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.
Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P;
Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889
[TBL] [Abstract][Full Text] [Related]
19. Psychosocial interventions for preventing and treating depression in dialysis patients.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Rabindranath KS; Strippoli GF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004542. PubMed ID: 31789430
[TBL] [Abstract][Full Text] [Related]
20. Non-surgical interventions for the management of chronic pelvic pain.
Cheong YC; Smotra G; Williams AC
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD008797. PubMed ID: 24595586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
